Stay updated with breaking news from Seattle Based Immusoft. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immusoft, a Seattle-based biotech company, has become the first to genetically engineer B cells and test them in a patient with a genetic disorder.
Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.